{"analyses":[{"ciLowerLimit":"0.75","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.02","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0770","paramType":"Hazard Ratio (HR)","paramValue":"0.87","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.85","upperLimit":"20.76","value":"18.73"},{"groupId":"OG001","lowerLimit":"19.02","upperLimit":"23.36","value":"21.03"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"451"},{"groupId":"OG001","value":"451"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization to the date of death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo Plus Nab-Paclitaxel"},{"description":"Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab Plus Nab-Paclitaxel"}],"paramType":"MEDIAN","populationDescription":"The ITT population is defined as all randomized patients, whether or not the assigned study treatment was received.","reportingStatus":"POSTED","timeFrame":"Baseline until death due to any cause (up to approximately 58 months)","title":"Overall Survival (OS) in All Randomized Participants","type":"PRIMARY","unitOfMeasure":"Months"}